Author(s): Harshada I Patil, Dhiraj Kamble

Email(s): drharshadapatilskcp@gmail.com

DOI: 10.52711/2231-5659.2022.00051   

Address: Harshada I Patil*, Dhiraj Kamble
Department of Pharmaceutics, Dr. Shivajirao Kadam College of Pharmacy, Kasbe Digraj, 416305 Sangli, Maharashtra, India.
*Corresponding Author

Published In:   Volume - 12,      Issue - 4,     Year - 2022


ABSTRACT:
Mucormycosis or Zygomycosis is defined as an insidious mycosis by members of the Mucorales and zygomycotic species. Mucormycosis is rare but severe invasive fungal infection. Infection with human corpuscles occurs in superficial form in the outer ear, nails, skin and visceral forms manifest in lung, gastrointestinal, and cerebral types. Mucormycosis is associated with exposure to high levels of airborne fungal contamination. In the context of COVID-19, India has seen an increasing number of incidents. The majority of the cases documented are related to the inappropriate use of corticosteroids in COVID-19 patients. Diabetes mellitus (73.5%), ma-lignancy (9.0%), and organ transplantation are among the main risk factors for mucormycosis in Indians (7.7 percent). In diabetic patients, Mucormycosis develops as a destructive and potentially fatal condition. Diabetic ketoacidosis accelerates fungal invasion. Risk factors include uncontrolled diabetes mellitus, especially ketoacidosis, steroid use, age, neutropenia Mucormycosis diagnosis involves a careful examination of clinical manifestations, magnetic resonance imaging modalities, early use of computed tomography (CT). Mucormycosis can impair the nose, sinuses, orbit, CNS, pulmonary, gastro-intestinal tract (GIT), skin, jaws bones, joints, heart, kidney, and mediastinum. Newer generation antifungal treatments such as amphotericin B, ketoconazole, itraconazole, and voriconazole. There are several formulations of amphotericin B available, including liposomal and lipid-based amphotericin, the colloidal diffusion of amphotericin for most common fungal infections. Breakthrough invasive fungal infections persist when new azoles, posaconazole, and isavuconazole are introduced, despite their anti-mucoral activity.


Cite this article:
Harshada I Patil, Dhiraj Kamble. A Brief Review on Covid-19 associated Mucormycosis. Asian Journal of Research in Pharmaceutical Sciences. 2022; 12(4):297-3. doi: 10.52711/2231-5659.2022.00051

Cite(Electronic):
Harshada I Patil, Dhiraj Kamble. A Brief Review on Covid-19 associated Mucormycosis. Asian Journal of Research in Pharmaceutical Sciences. 2022; 12(4):297-3. doi: 10.52711/2231-5659.2022.00051   Available on: https://ajpsonline.com/AbstractView.aspx?PID=2022-12-4-7


REFERENCES:
1.    Bitar D, Van Cauteren D, Lanternier F et al. Increasing incidence of zygomycosis (mucor- mycosis), France, 1997–2006. Emerg Infect Dis., 2009; 15: 1395–1401.
2.    Rammaert B, Lanternier F, Poirיe S, Kania R, Lortholary O. Diabetes and mucormycosis: a complex interplay. Diabetes & metabolism, 2012; 38(3): 193-204
3.    Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive-fungal infection after allogeneic hematopoietic cell transplantation. Blood, 2010; 116: 5111–18.
4.    Skiada A, Lanternier F, Groll AH, Pagano L, Zimmerli S, Herbrecht R, Lortholary O, Petrikkos GL. Diagnosis and treatment of mucormycosis in patients with haematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematological, 2013; 98(4): 492-504.
5.    Gangneux JP, Bougnoux ME, Dannaoui E, Cornet M, Zahar JR. Invasive fungal diseases during COVID-19: we should be prepared. J Mycol Med. 2020. Jun;30(2):100971.
6.    Koehler P, Cornely OA, Bottiger BW, Dusse F, Eichenauer DA, Fuchs F, et al. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020.
7.    Sipsas N, Gamaletsou M, Anastasopoulou A, Kontoyiannis D. Therapy of mucormycosis. Journal of Fungi, 2018; 4(3): 90.
8.    Pawan N. Karwa, Jyoti K. Soundarmal, Pallavi S. Shinde, Swapna R. Jalde. Mucormycosis: A Lethal Disease. Asian Journal of Pharmacy and Technology. 2022; 12(1):41-6. doi: 10.52711/2231-5713.2022.00008
9.    Neha Abhishek Sharma. Mucormycosis: Why Incidence Rate is more in Covid -19 patients. Asian Journal of Nursing Education and Research. 2021; 11(4):599-0. doi: 10.52711/2349-2996.2021.00139
10.    Hamilos G, Samonis G, Kontoyiannis DP. Pulmonary mucormycosis. Semin. Respir. Crit. Care Med., 2011; 32: 693–702
11.    Bialek R, Zelck UE. PCR-based diagnosis of mucormycosis in tissue samples. Pathologe. 2013; 34 (6): 511–8.
12.    Hammond SP, Bialek R, Milner DA, Petschnigg EM, Baden LR, Marty FM. Molecular methods to improve diagnosis and identification of mucormycosis. J Clin Microbiol. 2011; 49(6): 2151–3.
13.    Slavin, M.; Van Hal, S.; Sorrell, T.; Lee, A.; Marriott, D.; Daveson, K.; Kennedy, K.; Hajkowicz, K.; Halliday, C.; Athan, E.; et al. Invasive infections due to filamentous fungi other than Aspergillus: Epidemiology and determinants of mortality. Clin. Microbiol. Infect. 2015, 21, 490.e1–490.e10.
14.    Jeong, W.; Keighley, C.; Wolfe, R.; Lee, W.L.; Slavin, M.A.; Kong, D.C.; Chen, S.C.-A. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta analysis of case reports. Clin. Microbiol. Infect. 2019, 25, 26–34.
15.    Patel, A.; Kaur, H.; Xess, I.; Michael, J.S.; Savio, J.; Rudramurthy, S.; Singh, R.; Shastri, P.; Umabala, P.; Sardana, R. A multicenter observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin. Microbiol. Infect. 2020, 26, 944.e9–944.e15.
16.    Manisha Rokade, Pradnya Khandagale. Coronavirus Disease: A Review of a New Threat to Public Health. Asian J. Pharm. Res. 2020; 10(3):241-244. doi: 10.5958/2231-5691.2020.00042.8
17.    B. V. Naresh. A Review of the 2019 Novel Coronavirus (COVID-19) Pandemic. Asian J. Pharm. Res. 2020; 10(3):233-238. doi: 10.5958/2231-5691.2020.00040.4
18.    Naveen Yadam, Ganta Suhasin. Prediction of COVID-19 severity associated with Pneumonia by chest CT scan and Serological results. Asian Journal of Pharmacy and Technology. 2021; 11(3):198-2. doi: 10.52711/2231-5713.2021.00032
19.    Subhashis Debnath, Jaya Saha. Coronavirus disease (COVID-19): A global threat. Asian Journal of Pharmacy and Technology. 2022; 12(1):63-9. doi: 10.52711/2231-5713.2022.00011
20.    Sholly. CK. An evaluation of Mucormycosis, Outburst. Asian Journal of Nursing Education and Research. 2021; 11(4):591-3. doi: 10.52711/2349-2996.2021.00137
21.    Sunayana Mali, Audumbar Mali, Manojkumar Patil, Ritesh Bathe, Dipak Bathe. An updated review on current situation of Corona virus disease. Asian Journal of Pharmacy and Technology. 2022; 12(2):167-5. doi: 10.52711/2231-5713.2022.00028
22.    Ali Adel Dawood. Using Remdesivir and Dexamethasone for Treatment of SARS-CoV-2 Shortens the patient's stay in the Hospital. Asian Journal of Pharmaceutical Research. 2021; 11(2):138-0. doi: 10.52711/2231-5691.2021.00026
23.    M. Machado, M. Valerio, A. Alvarez-Uria, M. Olmedo, C. Veintimilla, B. Padilla, et al., Invasive pulmonary aspergillosis in the COVID-19 era: an expected new entity, Mycoses 64 (2021) 132–143.
24.    Gupta, Amod; Sharma, Aman1; Chakrabarti, Arunaloke2 The emergence of post-COVID-19 mucormycosis in India: Can we prevent it?, Indian Journal of Ophthalmology: July 2021 - Volume 69 - Issue 7 - p 1645-1647 doi: 10.4103/ijo.IJO_1392_21
25.    Sholly. CK. An evaluation of Mucormycosis, Outburst. Asian Journal of Nursing Education and Research. 2021; 11(4):591-3. doi: 10.52711/2349-2996.2021.00137
26.    Awadhesh Kumar Singh, Ritu Singh, Shashank R. Joshi, Anoop Misra, Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India, Diabetes & Metabolic Syndrome: Clinical Research & Reviews, Volume 15, Issue 4,
27.    Prakash H, Ghosh AK, Rudramurthy SM, et al. A prospective multicenter study on mucormycosis in India: epidemiology, diagnosis, and treatment. Med Mycol 2019; 57: 395–402.
28.    Prakash H, Chakrabarti A. Epidemiology of Mucormycosis in India. Microorganisms. 2021;9(3):523. Published 2021 Mar 4. doi:10.3390/microorganisms9030523



Recomonded Articles:

Author(s): Mohd. Yaqub Khan, Maryada Roy, Brijesh Kumar Saroj, Sudhakar Dubey, Vineet Kumar Sharma

DOI: 10.5958/2231-5659.2015.00019.3         Access: Open Access Read More

Author(s): Pradeep Sahu, Neha Pinkalwar, Ravindra Dhar Dubey, Shweta Paroha, Shilpi Chatterjee, Tanushree Chatterjee

DOI:         Access: Open Access Read More

Author(s): K.Vijaya Sri, Guda Santhoshini, D. Ravi Sankar, K.Niharika

DOI: 10.5958/2231-5659.2018.00005.X         Access: Open Access Read More

Author(s): Nikunja B. Pati, T. Swayam Jyothi, Gajender Singh Thakur, Sushma Reddy, G. Meghna

DOI: 10.5958/2231-5659.2017.00028.5         Access: Open Access Read More

Author(s): Roshani Bhalerao, Akshay Patil, Dinesh Rishipathak, Sanjay Kshirsagar

DOI: 10.5958/2231-5659.2017.00029.7         Access: Open Access Read More

Author(s): Rajendra Jangde

DOI:         Access: Open Access Read More

Author(s): Dasari Nirmala, Enjamuri Aslesha , M. Sudhakar

DOI:         Access: Open Access Read More

Author(s): Sarika S. Lokhande

DOI: 10.5958/2231-5659.2019.00032.8         Access: Open Access Read More

Author(s): Usama Shoukath, Umama Shoukath, Salma Sultana, Mohammed Nayeem Uddin

DOI: 10.5958/2231-5659.2018.00014.0         Access: Open Access Read More

Author(s): Raut Indrayani D., Bandgar Sandip A., Shah R. R., Chougule D.D.

DOI:         Access: Open Access Read More

Author(s): S.C. Shivhare, U.D.Shivhare, Preeti Srivastav, K.G. Malviya

DOI:         Access: Open Access Read More

Author(s): Sai Saran Thokada, Harsha Kandregula, Vinodkumar Mugada

DOI: 10.5958/2231-5659.2018.00042.5         Access: Open Access Read More

Asian Journal of Research in Pharmaceutical Sciences (AJPSci) is an international, peer-reviewed journal, devoted to pharmaceutical sciences....... Read more >>>

RNI: Not Available                     
DOI: 10.52711/2231-5659 


Recent Articles




Tags